|
Stereotactic radiotherapy plus anti PD-1 therapy in patients with locally advanced unresectable pancreatic cancer: Results from a phase 1/2 clinical trial (CA209-9KH). |
|
|
Consulting or Advisory Role - Accord Healthcare; AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer |
Speakers' Bureau - Gilead Sciences; Merck Sharp & Dohme; Sanofi |
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pfizer |
|
|
Consulting or Advisory Role - Merck Serono; Merck Sharp & Dohme |
Speakers' Bureau - Amgen; Merck Serono; Merck Sharp & Dohme; Pierre Fabre; SERVIER |
Travel, Accommodations, Expenses - Amgen; SERVIER |
|
|
No Relationships to Disclose |
|
Beatrice Mohelníková-Duchoňová |
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/; Merck Serono; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck; Merck Sharp & Dohme; Roche; Sanofi |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck Sharp & Dohme; Sanofi |
Travel, Accommodations, Expenses - Gilead Sciences; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - BioNTech; Novo Nordisk; Pfizer; Roche |
Honoraria - AstraZeneca; GlaxoSmithKline; Merck Sharp & Dohme |
Consulting or Advisory Role - GlaxoSmithKline; Merck Sharp & Dohme |